|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein phosphatase 2A (PP2A) is a human tumor suppressor that inhibits cellular transformation by regulating the activity of several signaling proteins critical for malignant cell behavior.
|
21233840 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, our findings reveal the existence of a hitherto unrecognized molecular cross-talk between the oncogenic SHH pathway and the tumor suppressor PP2A and suggest a novel mechanism underlying the anticancerogenic effects of rapamycin.
|
18559511 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We established cultures of three SBOTs and one LGC from tumor biopsies, and inactivated p53, Rb and PP2A in the cells with SV40 large T (LT) and small T (ST) antigen.
|
18678400 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PP2A: the expected tumor suppressor.
|
15661531 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MCV sT, however, only displaces a restricted subset of PP2A B subunits, which is insufficient to cause tumor cell formation in vitro.
|
25631078 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By inactivating c-MYC and other key signaling pathways, PP2A plays an important tumor suppressor function.
|
24927563 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, our results provide a preclinical proof of concept for the efficacy of SMAP in AR degradation and CRPC treatment.<b>Significance:</b> A novel class of small-molecule activators of the tumor suppressor PP2A, a serine/threonine phosphatase that inhibits many oncogenic signaling pathways, is shown to deregulate the phosphoproteome and to destabilize the androgen receptor in advanced prostate cancer.<i></i>.
|
29358171 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies have indicated that inflammatory stimulation represses protein phosphatase 2A (PP2A), a well-known tumor suppressor.
|
26761431 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PP2A is a major tumor suppressor whose inactivation is frequently found in a wide spectrum of human tumors.
|
29229993 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Somatic mutations in PPP2R1A, which encodes a scaffolding subunit of serine/threonine protein phosphatase 2A (PP2A), have recently been described in different types of gynecological neoplasias.
|
23267135 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of PP2A A subunits in tumor suppression.
|
19262135 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we summarize the role of the tumor suppressor PP2A in modulating ER and AR signaling in breast cancer, the molecular mechanisms involved, and its biological and therapeutic impact.
|
28916342 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings may have important implications in regard to the role of PP2A as a tumor suppressor.
|
11313937 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The forkhead box L1 (FOXL1) and protein phosphatase 2A (PP2A) have been recognized to be tumor suppressive in human pancreatic cancers.
|
26820810 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
|
24667985 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cancerous inhibitor of PP2A (p90/CIP2A) was recently characterized as an innovative oncoprotein in human malignancies. p90/CIP2A inhibited c-Myc-associated PP2A phosphatase activity to promote cell proliferation and tumor growth.
|
25086622 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with an orally bioavailable small-molecule activator of PP2A DT-061, in combination with the MEK inhibitor AZD6244, resulted in suppression of both p-AKT and MYC, as well as tumor regression in two KRAS-driven lung cancer mouse models.
|
30021885 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein phosphatase 2A (PP2A), a tumor suppressor, has been shown to be downregulated in many human cancers via multiple mechanisms including upregulation of its endogenous inhibitors, I2PP2A or CIP2A.
|
30286326 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Earlier studies have shown both p53-dependent and -independent tumor-suppressive functions of B56gamma-specific protein phosphatase 2A (B56gamma-PP2A).
|
20473327 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data provide the first compelling mouse genetics evidence sustaining the tumor suppressive activity of a single PP2A holoenzyme, constituting the final missing incentive for full clinical development of PP2A as cancer biomarker and therapy target.
|
28967903 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Multiple pathways regulated by the tumor suppressor PP2A in transformation.
|
18329957 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we argue that, besides kinases, phosphatases should no longer be ignored in clinical trials, particularly in type II ECs, where the tumour suppressive phosphatase protein phosphatase type 2A (PP2A) is frequently mutated.
|
30104481 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein phosphatase 2A (PP2A) functions as a tumor suppressor, and it was previously suggested to regulate eIF4E phosphorylation.
|
20927323 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results provide evidence for <i>PPP2R4</i> as a haploinsufficient tumor suppressor gene, defining a high-penetrance genetic mechanism for PP2A inhibition in human cancer.<i></i>.
|
29046336 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on these considerations, and a very recently emerged role of oncogenic function of a group of phosphatase inhibitor proteins as human oncoproteins, we propose that in order to efficiently inhibit phosphorylation-dependent signaling in cancer cells, and thus provide better therapeutic index, the kinase inhibitors should be combined with strategies to reactivate tumor suppressor phosphatases such as Protein Phosphatase 2A (PP2A).
|
30055114 |
2018 |